BioAge Labs (BIOA) director awarded 22,000 stock options at $15.48

Rhea-AI Filing Summary

BioAge Labs, Inc. director Jean Pierre Garnier received a grant of stock options covering 22,000 shares of common stock at an exercise price of $15.48 per share. The options vest in full on the earlier of the next annual stockholder meeting or one year from the grant date, subject to continued service, and expire on June 9, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GARNIER JEAN PIERRE

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	22,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 22,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 22,000 options Exercise price: $15.48 per share Underlying shares: 22,000 shares +2 more

5 metrics

Option grant size 22,000 options Stock Option (Right to Buy) granted to director

Exercise price $15.48 per share Conversion or exercise price of the option

Underlying shares 22,000 shares Common stock underlying the option grant

Expiration date June 9, 2036 Option expiration for the 22,000-share award

Shares following transaction 22,000 options Total derivative securities held after this grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, grant, award, or other acquisition, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 15.4800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The entire option award shall vest on the earlier of..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

expiration date financial

"expiration_date: 2036-06-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GARNIER JEAN PIERRE

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.48	06/10/2026		A		22,000		(1)	06/09/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioAge Labs (BIOA) director Jean Pierre Garnier report on this Form 4?

Jean Pierre Garnier reported receiving a grant of stock options for 22,000 shares of BioAge Labs common stock. The options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price.

What is the exercise price and size of the BioAge Labs (BIOA) stock option grant?

The grant covers 22,000 shares of BioAge Labs common stock at an exercise price of $15.48 per share. This means Garnier can choose to buy up to 22,000 shares at $15.48 regardless of future market prices, once vested.

When do Jean Pierre Garnier’s BioAge Labs (BIOA) options vest?

The entire option award vests on the earlier of the next annual meeting of BioAge Labs stockholders or the one-year anniversary of the grant date. Vesting depends on Garnier’s continued service with the company through the applicable vesting date.

When do the newly granted BioAge Labs (BIOA) stock options expire?

The options expire on June 9, 2036, giving a long-term exercise window. After that date, any unexercised portion of the 22,000-share award will lapse and can no longer be used to purchase BioAge Labs common stock.

Is this BioAge Labs (BIOA) Form 4 a buy or a sale of shares?

This Form 4 reflects a grant or award acquisition of stock options, not a market buy or sale. No shares were purchased or sold on the open market; instead, Garnier received derivative rights to buy shares in the future at $15.48 per share.